Loading...

We've got a brand new version of Simply Wall St! Try it out

Gentian Diagnostics

OB:GENT-ME
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GENT-ME
OB
NOK722M
Market Cap
  1. Home
  2. NO
  3. Healthcare
Company description

Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research. The last earnings update was 30 days ago. More info.


Add to Portfolio Compare Print
GENT-ME Share Price and Events
7 Day Returns
-0.2%
OB:GENT-ME
-1.7%
Europe Medical Equipment
2.6%
NO Market
1 Year Returns
-17%
OB:GENT-ME
3.4%
Europe Medical Equipment
-9.1%
NO Market
GENT-ME Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Gentian Diagnostics (GENT-ME) -0.2% -4.1% -6.2% -17% - -
Europe Medical Equipment -1.7% 1.2% 2.7% 3.4% 57.5% 93%
NO Market 2.6% 8% 2.6% -9.1% 31.3% 13.2%
1 Year Return vs Industry and Market
  • GENT-ME underperformed the Medical Equipment industry which returned 3.4% over the past year.
  • GENT-ME underperformed the Market in Norway which returned -9.1% over the past year.
Price Volatility
GENT-ME
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Gentian Diagnostics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Gentian Diagnostics. This is due to cash flow or dividend data being unavailable. The share price is NOK46.9.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Gentian Diagnostics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Gentian Diagnostics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OB:GENT-ME PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in NOK NOK-1.51
OB:GENT-ME Share Price ** OB (2019-09-13) in NOK NOK46.9
Europe Medical Equipment Industry PE Ratio Median Figure of 59 Publicly-Listed Medical Equipment Companies 31.48x
Norway Market PE Ratio Median Figure of 149 Publicly-Listed Companies 13.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Gentian Diagnostics.

OB:GENT-ME PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:GENT-ME Share Price ÷ EPS (both in NOK)

= 46.9 ÷ -1.51

-31.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gentian Diagnostics is loss making, we can't compare its value to the Europe Medical Equipment industry average.
  • Gentian Diagnostics is loss making, we can't compare the value of its earnings to the Norway market.
Price based on expected Growth
Does Gentian Diagnostics's expected growth come at a high price?
Raw Data
OB:GENT-ME PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -31.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Medical Equipment Industry PEG Ratio Median Figure of 42 Publicly-Listed Medical Equipment Companies 2.16x
Norway Market PEG Ratio Median Figure of 110 Publicly-Listed Companies 0.72x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Gentian Diagnostics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Gentian Diagnostics's assets?
Raw Data
OB:GENT-ME PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in NOK NOK15.53
OB:GENT-ME Share Price * OB (2019-09-13) in NOK NOK46.9
Europe Medical Equipment Industry PB Ratio Median Figure of 160 Publicly-Listed Medical Equipment Companies 3.62x
Norway Market PB Ratio Median Figure of 238 Publicly-Listed Companies 1.13x
OB:GENT-ME PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:GENT-ME Share Price ÷ Book Value per Share (both in NOK)

= 46.9 ÷ 15.53

3.02x

* Primary Listing of Gentian Diagnostics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gentian Diagnostics is good value based on assets compared to the Europe Medical Equipment industry average.
X
Value checks
We assess Gentian Diagnostics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Gentian Diagnostics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Gentian Diagnostics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gentian Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.3%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Gentian Diagnostics expected to grow at an attractive rate?
  • Unable to compare Gentian Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Gentian Diagnostics's earnings growth to the Norway market average as no estimate data is available.
  • Unable to compare Gentian Diagnostics's revenue growth to the Norway market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OB:GENT-ME Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 20.3%
Europe Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
Norway Market Earnings Growth Rate Market Cap Weighted Average 15.1%
Norway Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OB:GENT-ME Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OB:GENT-ME Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2019-06-30 48 -17 -41
2019-03-31 47 -12 -23
2018-12-31 46 -11 -20
2018-09-30 51 -18 -12
2018-06-30 41 -19 -16
2018-03-31 40 -16 -14
2017-12-31 35 -19 -15
2017-09-30 34 -19 -13
2017-06-30 32 -18 -12
2017-03-31 30 -16 -13
2016-12-31 31 -8 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Gentian Diagnostics is high growth as no earnings estimate data is available.
  • Unable to determine if Gentian Diagnostics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OB:GENT-ME Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Gentian Diagnostics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:GENT-ME Past Financials Data
Date (Data in NOK Millions) EPS *
2019-06-30
2019-03-31 -1.51
2018-12-31 -1.29
2018-09-30 -0.78
2018-06-30 -1.07
2018-03-31 -0.98
2017-12-31 -1.08
2017-09-30 -0.90
2017-06-30 -0.89
2017-03-31 -0.96
2016-12-31 -0.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Gentian Diagnostics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Gentian Diagnostics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Gentian Diagnostics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Gentian Diagnostics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Gentian Diagnostics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Gentian Diagnostics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Gentian Diagnostics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Gentian Diagnostics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Gentian Diagnostics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Gentian Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Gentian Diagnostics's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Gentian Diagnostics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Gentian Diagnostics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:GENT-ME Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 47.81 -41.24 35.95 0.61
2019-03-31 46.64 -23.20 33.89 0.84
2018-12-31 45.82 -19.80 31.16
2018-09-30 50.99 -12.05 15.35 8.73
2018-06-30 40.54 -16.43 9.86 8.73
2018-03-31 39.88 -13.72 15.20 3.27
2017-12-31 34.99 -15.17 22.30
2017-09-30 33.70 -12.64 28.28
2017-06-30 31.76 -12.42 26.23
2017-03-31 30.19 -13.41 22.34
2016-12-31 30.90 -8.93 17.06
2015-12-31 25.59 -3.22 13.20
2014-12-31 24.55 -2.91 9.98
2013-12-31 22.89 0.87 8.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Gentian Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Gentian Diagnostics has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Gentian Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Gentian Diagnostics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Gentian Diagnostics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Gentian Diagnostics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Gentian Diagnostics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Gentian Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Gentian Diagnostics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Gentian Diagnostics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 342.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Gentian Diagnostics Company Filings, last reported 2 months ago.

OB:GENT-ME Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 219.13 0.62 178.95
2019-03-31 239.11 0.66 191.01
2018-12-31 245.87 0.00 198.31
2018-09-30 258.17 0.74 194.49
2018-06-30 258.52 0.78 201.05
2018-03-31 192.55 0.44 138.63
2017-12-31 196.48 0.00 145.00
2017-09-30 201.71 0.00 146.96
2017-06-30 206.71 0.00 154.12
2017-03-31 206.30 0.00 159.08
2016-12-31 115.54 0.00 74.35
2015-12-31 95.06 0.00 66.33
2014-12-31 7.39 6.08 1.96
2013-12-31 1.62 9.91 1.74
  • Gentian Diagnostics's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (177.7% vs 0.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Gentian Diagnostics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Gentian Diagnostics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -3.5% each year.
X
Financial health checks
We assess Gentian Diagnostics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Gentian Diagnostics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Gentian Diagnostics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Gentian Diagnostics dividends.
If you bought NOK2,000 of Gentian Diagnostics shares you are expected to receive NOK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Gentian Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Gentian Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OB:GENT-ME Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.5%
Norway Market Average Dividend Yield Market Cap Weighted Average of 115 Stocks 4.5%
Norway Minimum Threshold Dividend Yield 10th Percentile 1.5%
Norway Bottom 25% Dividend Yield 25th Percentile 2.5%
Norway Top 25% Dividend Yield 75th Percentile 6.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Gentian Diagnostics has not reported any payouts.
  • Unable to verify if Gentian Diagnostics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Gentian Diagnostics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Gentian Diagnostics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Gentian Diagnostics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Gentian Diagnostics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Gentian Diagnostics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Gentian Diagnostics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hilja Ibert
TENURE AS CEO 1.2 years
CEO Bio

Dr. Hilja Ibert has been the Chief Executive Officer of Gentian Diagnostics AS since July 16, 2018. Dr. Ibert has more than 25 years' experience from the international diagnostic industry, and an extensive and strong leadership experience. Dr. Ibert has previously held the position as Vice President International Diagnostic Solutions at Hologic, as well as several senior positions within Becton Dickinson and bioMerieux within the field of diagnostics. Dr. Ibert holds a PhD degree in Nutrition Science from the University of Bonn, Germany. Dr. Ibert also has experience with early stage R&D companies, lastly in her position as Chief Executive Officer for miDiagnostics in Belgium.

CEO Compensation
  • Insufficient data for Hilja to compare compensation growth.
  • Insufficient data for Hilja to establish whether their remuneration is reasonable compared to companies of similar size in Norway.
Management Team

Hilja Ibert

TITLE
Chief Executive Officer
TENURE
1.2 yrs

Njaal Kind

TITLE
Chief Financial Officer

Bård Sundrehagen

TITLE
Executive Vice President of Business Development
TENURE
1.2 yrs
Board of Directors

Tomas Settevik

TITLE
Chairman
AGE
59

Kari Krogstad

TITLE
Director

Espen Jørgensen

TITLE
Director
AGE
44

Bendik Sundrehagen

TITLE
Director

Henrik Krefting

TITLE
Director
TENURE
0.3 yrs

Susanne Stuffers

TITLE
Director
TENURE
0.3 yrs

Ingrid Akay

TITLE
Director
Who owns this company?
Recent Insider Trading
  • Gentian Diagnostics individual insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NOK) Value (NOK)
11. Sep 19 Buy P53 Invest AS Company 10. Sep 19 10. Sep 19 23,255 NOK43.00 NOK999,965
11. Sep 19 Buy Teakay Invest As Company 10. Sep 19 10. Sep 19 2,325 NOK43.00 NOK99,975
11. Sep 19 Buy Henrik Krefting Individual 10. Sep 19 10. Sep 19 40,000 NOK43.00 NOK1,720,000
11. Sep 19 Buy Kari Krogstad Individual 10. Sep 19 10. Sep 19 2,325 NOK43.00 NOK99,975
11. Sep 19 Buy Hilja Ibert Individual 10. Sep 19 10. Sep 19 5,813 NOK43.00 NOK249,959
11. Sep 19 Buy Njaal Kind Individual 10. Sep 19 10. Sep 19 10,000 NOK43.00 NOK430,000
11. Sep 19 Buy Vatne Capital AS Company 10. Sep 19 10. Sep 19 204,654 NOK43.00 NOK8,800,122
11. Sep 19 Buy Mutus AS Company 10. Sep 19 10. Sep 19 23,255 NOK43.00 NOK999,965
11. Sep 19 Sell Erling Sundrehagen Individual 10. Sep 19 10. Sep 19 -311,627 NOK43.00 NOK-13,399,961
29. Jan 19 Buy Vatne Capital AS Company 29. Jan 19 29. Jan 19 175,000 NOK54.50 NOK9,537,501
28. Feb 19 Buy Njaal Kind Individual 28. Feb 19 28. Feb 19 10,000 NOK56.00 NOK560,000
X
Management checks
We assess Gentian Diagnostics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Gentian Diagnostics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research. It offers in-vitro diagnostic (IVD) and molecular diagnostic tests for medical laboratories and universities worldwide. The company’s products include Calprotectin, a particle enhanced turbidimetric immunoassay (PETIA) for quantitative analysis of total calprotectin in plasma; and Canine CRP, an IVD test for the quantitative determination of Canine CRP in dog serum plasma. It also offers NGAL, a PETIA for IVD testing of neutrophil gelatinase-associated lipocalin in human urine and plasma samples; Cystatin C, a PETIA for use on a range of clinical chemistry analyzers; PreTect HPV-Proofer, an assay for the qualitative detection of the presence of human papillomavirus; and PreTect SEE, a control test for NILM cytology. The company was founded in 2001 and is headquartered in Moss, Norway.

Details
Name: Gentian Diagnostics AS
GENT-ME
Exchange: OB
Founded: 2001
NOK722,068,694
15,395,921
Website: http://www.gentian.com
Address: Gentian Diagnostics AS
Bjornasveien 5,
Moss,
Østfold, 1596,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB GENT-ME Share Capital Oslo Bors NO NOK 14. Dec 2016
Number of employees
Current staff
Staff numbers
44
Gentian Diagnostics employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/14 21:37
End of day share price update: 2019/09/13 00:00
Last earnings filing: 2019/08/15
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.